Company News: Bristol-Myers Squibb, Mead Johnson and Covidien
Covidien, which owns marketing rights to experimental pain drug Exalgo, said the drug's developer is in discussions with FDA staff regarding a pending application. According to Covidien, the agency told Exalgo developer Neuromed that its NDA was not sufficient to form the basis for approval. The FDA will complete its review of the opioid drug on November 22. Covidien, whose Mallinckrodt unit obtained the US commercial rights to Exalgo in June, is working with Neuromed to determine next steps.